Find, compare & contact
Veldoreotide API Manufacturers & Suppliers

teaser-1024x654-1
Contact suppliers
No suppliers found
Sorry, there are currently no suppliers listed for this ingredient. Hopefully we can help you with other ingredients.
Notify me!
Want to be the first to find out when a supplier for Veldoreotide is listed?

Join our notification list by following this page.

List your company
Are you a supplier of Veldoreotide or other APIs and are you looking to list your company on Pharmaoffer?

Click the button below to find out more

Find CDMO
Looking for a CDMO/CMO that can help you with your pharmaceutical needs?

Click the button below to switch over to the contract services area of Pharmaoffer.

Looking for Veldoreotide API 252845-37-7?

Description:
Here you will find a list of producers, manufacturers and distributors of Veldoreotide. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
API | Excipient name:
Veldoreotide 
Synonyms:
 
Cas Number:
252845-37-7 
DrugBank number:
DB12777 
Unique Ingredient Identifier:
1Z83587HBN

General Description:

Veldoreotide, identified by CAS number 252845-37-7, is a notable compound with significant therapeutic applications. Somatoprim is under investigation for the treatment of Acromegaly.

Classification:

Veldoreotide belongs to the class of organic compounds known as oligopeptides. These are organic compounds containing a sequence of between three and ten alpha-amino acids joined by peptide bonds, classified under the direct parent group Oligopeptides. This compound is a part of the Organic compounds, falling under the Organic acids and derivatives superclass, and categorized within the Carboxylic acids and derivatives class, specifically within the Amino acids, peptides, and analogues subclass.

Categories:

Veldoreotide is categorized under the following therapeutic classes: Amino Acids, Peptides, and Proteins, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Hypothalamic Hormones, Nerve Tissue Proteins, Neuropeptides, Pancreatic Hormones, Peptide Hormones, Peptides, Pituitary Hormone Release Inhibiting Hormones, Proteins. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.

Veldoreotide is a type of Hormonal Agents


Hormonal agents are a prominent category of pharmaceutical active pharmaceutical ingredients (APIs) widely used in the medical field. These substances play a crucial role in regulating and modulating hormonal functions within the body. Hormonal agents are designed to mimic or manipulate the effects of naturally occurring hormones, allowing healthcare professionals to treat various endocrine disorders and hormonal imbalances.

Hormonal agents are commonly employed in the treatment of conditions such as hypothyroidism, hyperthyroidism, diabetes, and hormonal cancers. These APIs work by interacting with specific hormone receptors, either by stimulating or inhibiting their activity, to restore the balance of hormones in the body. They can be administered orally, intravenously, or through other routes depending on the specific medication and patient needs.

Pharmaceutical companies employ rigorous manufacturing processes and quality control measures to ensure the purity, potency, and safety of hormonal agent APIs. These APIs are synthesized using chemical or biotechnological methods, often starting from natural hormone sources or through recombinant DNA technology. Stringent regulatory guidelines are in place to guarantee the efficacy and safety of hormonal agent APIs, ensuring that patients receive high-quality medications.

As the demand for hormone-related therapies continues to grow, ongoing research and development efforts focus on enhancing the effectiveness and reducing the side effects of hormonal agent APIs. This includes the exploration of novel delivery systems, advanced formulations, and targeted drug delivery methods. By continuously advancing our understanding and capabilities in hormonal agents, the medical community can improve patient outcomes and quality of life for individuals with hormonal disorders.